Reinsurance Group of America (RGA) delivered a strong finish to 2025, reporting Q4 operating EPS of $7.75, marking a second consecutive record quarter, and achieving a trailing 12-month adjusted operating ROE of 15.7%, which exceeds the company's 13-15% target. Full-year results highlighted record operating EPS and an 18% increase in the value of in-force business margins, driven by $2.5 billion in capital deployments and robust growth in EMEA (pretax earnings up 35%) and APAC (up 18%). The Equitable transaction continued to perform in line with expectations, contributing significantly to earnings, while the U.S. Traditional segment faced headwinds from group healthcare claims, leading to a strategic decision to exit the group health lines following a 40% rate hike. Looking to 2026, management projects a run-rate EPS starting point of approximately $24.75, with expectations for $1.5 billion in in-force deployments, a 7% variable investment income return, and a continued commitment to shareholder returns through a 20-30% payout ratio.
| Metric | Value | Change |
|---|---|---|
| Q4 Operating EPS | $7.75 | Record Quarter |
| 2025 Adjusted ROE | 15.7% | Above Target (13-15%) |
| In-Force Margin Growth | 18% | Value increased $6.6B |
| Excess Capital | $2.7 Billion | Strong Balance Sheet |
| 2025 Run Rate EPS | $24.75 | N/A |
| 2026 Variable Investment Income Assumption | 7% | Up from 6% in 2025 |
| Share Repurchases (2025 Total) | $125 Million | Reinstated in Q3 |
RGA is executing a disciplined capital allocation strategy that balances growth with shareholder returns. In 2025, the company deployed $2.5 billion into in-force transactions, including the transformative Equitable deal, while simultaneously reinstating share buybacks, repurchasing $125 million since Q3. Management targets a total shareholder return (dividends plus buybacks) of 20-30% of after-tax operating earnings, signaling a mature approach to capital stewardship that prioritizes ROE accretion and excess capital management.
The decision to exit U.S. group healthcare lines represents a significant strategic pivot to improve portfolio quality. Despite implementing a 40% rate hike to address losses, management chose to wind down the $400 million premium block, indicating a strict adherence to risk appetite and a preference for deploying capital into higher-returning biometric and asset-intensive businesses where RGA holds a competitive advantage.
The Equitable transaction is proving to be a major value driver, with earnings in the second half of 2025 meeting the $60-70 million guidance and 2026 expectations set at $160-170 million. The success of this integration validates RGA's 'sweet spot' strategy of reinsuring blocks with both asset and biometric risk, allowing them to leverage their balance sheet and underwriting expertise to generate outsized returns.
Geographic diversification is increasingly driving RGA's growth, with EMEA and APAC outperforming. EMEA pretax earnings rose 35% on strong new business and longevity swaps, while APAC grew 18% driven by product development and favorable regulatory dynamics in Japan and Korea. This reduces reliance on the mature U.S. market and demonstrates the resilience of the global platform.
Management signaled a normalization of earnings drivers, specifically regarding 'in-force management actions,' which contributed $135 million in 2025 but are expected to have a 'more limited' impact in 2026. This shifts the growth narrative towards organic flow and the ramp-up of recent capital deployments, requiring investors to focus on the underlying run-rate earnings of approximately $24.75.
The U.S. Group Healthcare segment experienced significant deterioration, necessitating a drastic 40% rate hike and an ultimate decision to exit the business entirely. While the exit removes future volatility, the repricing and losses indicate a lapse in initial underwriting discipline or pricing power in that specific line, raising questions about risk management in other niche or asset-intensive blocks.
Earnings quality remains partially dependent on variable investment income, which was $48 million above expectations in Q4. Management's 2026 assumption of a 7% return relies on specific asset sales, and they noted that returns are currently suppressed by a 'muted environment for real estate sales.' This introduces volatility and execution risk into the earnings stream.
The Corporate and Other segment reported a $54 million operating loss in Q4, driven by higher financing costs. Management guided for this drag to persist at $50-55 million per quarter in 2026, representing a consistent headwind that operating segments must overcome to achieve net growth.
Management noted that the 'timing and size' of in-force management actions are 'highly unpredictable.' With these actions contributing significantly to recent results (e.g., $225 million in 2024), the guidance for a 'more limited' impact in 2026 creates a hurdle for growth, potentially making it harder to replicate the double-digit EPS growth seen in prior periods without offsetting gains.
Overall: Management exhibited a high degree of confidence and satisfaction throughout the call, frequently characterizing results as 'record,' 'excellent,' and 'strong.' They were notably transparent regarding the challenges in the U.S. Group Health segment, frankly discussing the decision to exit the business line after repricing efforts. The tone shifted from celebratory regarding the 2025 achievements to pragmatic and disciplined when outlining 2026 guidance, particularly emphasizing the normalization of in-force management actions.
Confidence: HIGH - Management consistently exceeded their financial targets (ROE of 15.7% vs. 13-15% target) and provided specific, detailed guidance for 2026 without hesitation. Their language was decisive regarding strategic shifts, such as the exit from Group Health, and they expressed strong conviction in the 'risk-adjusted returns' of recent vintages of new business.
22% to 23%
7%
~$1.5 Billion
$50 Million to $55 Million per quarter
8% to 10%
13% to 15%
$160 Million to $170 Million
Hedging & Uncertainty: Management generally used direct, confident language ('record quarter,' 'successfully delivering'), but employed specific hedges regarding the sustainability of non-core earnings. They described in-force management actions as 'highly unpredictable' in terms of timing and size, and used temporal hedges like 'will primarily emerge in 2027' when discussing the financial impact of the Group Health exit, distancing current guidance from the full cost of the wind-down. They also softened the 2026 outlook by stating it assumes a 'smaller contribution' from management actions compared to the 'elevated' levels of recent years.
We are confident that our most recent vintages of new business will generate risk-adjusted returns that meet or exceed our targets. - Tony Cheng, CEO
We fully reprice this business for 2026 and expect a significant improvement in results over the next year. - Tony Cheng, CEO
We have decided to exit the group health care lines of business. - Tony Cheng, CEO
The timing and size of these actions is highly unpredictable. - Axel Andre, CFO
We intend to remain opportunistic with share repurchases. - Axel Andre, CFO
We are projecting a more limited financial impact compared to recent experience. - Axel Andre, CFO
Analyst Sentiment: Analysts were highly engaged, probing the mechanics of the Equitable transaction's performance relative to the primary company, and seeking clarity on the specific rate actions and timing of the Group Health exit. There was also significant interest in the sustainability of capital deployment levels and the 'run-rate' earnings power.
Management Responses: Management responses were detailed and transparent, readily providing granular data such as the 40% rate hike in Group Health and the specific earnings run-rate of the exited business ($25 million). They effectively defended the Equitable transaction's 'uncorrelated' results by explaining the four drivers of upside, including repricing and asset repositioning.
Detailed discussion on the Group Health exit, including the 40% rate increase and the strategic rationale for winding down the business.
Analysis of the Equitable block, specifically why RGA's mortality experience differed from Equitable's and the drivers of the $160-170M earnings guidance for 2026.
Capital allocation strategy, focusing on the balance between the $1.5B deployment target and the 20-30% shareholder payout ratio.
In-force management actions and the expectation for a 'more limited' financial impact in 2026 compared to 2024/2025.
Investment portfolio performance, specifically the 7% variable income assumption and exposure to software lending/AI.
RGA is firing on all cylinders, delivering record profitability (15.7% ROE) and successfully integrating large, complex transactions like Equitable. The strategic decision to exit the underperforming Group Health segment, while painful in the short term, demonstrates disciplined capital allocation and removes a volatile drag on earnings. The company's diversified global platform is generating strong growth, particularly in APAC and EMEA, while the capital position remains robust with $2.7 billion in excess. Although earnings growth may normalize as in-force management actions moderate, the $24.75 run-rate EPS provides a solid foundation for the 8-10% intermediate-term growth target. The combination of a clear strategic focus, strong underwriting expertise, and commitment to shareholder returns makes RGA a compelling holding.
Management noted that higher interest rates are beneficial for earnings due to positive reinvestment cash flows and illiquid liability profiles. They also stated that exposure to disintermediation risk in Japan is modest at current rate levels.
Jonathan Porter noted that flu hospitalizations peaked at the higher end of a normal range but have since declined substantially. There is no evidence of increased virulence compared to other seasonal strains.
Regulatory changes in Japan and Korea are creating 'considerable opportunities' for risk transfer as clients adjust their balance sheets. RGA feels well-positioned to leverage these dynamics.